A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
- Conditions
- Hypertension
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1000
- Registration Number
- NCT00240474
- Locations
- 🇫🇮
Hämeenlinnan lääkäriasema Oy, Linnan klinikka, Hämeenlinna, Finland
🇫🇮Kouvolan lääkäriasema, Kouvola, Finland
🇫🇮Hatanpään terveyskeskussairaala, Tampere, Finland
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 491
- Registration Number
- NCT00240435
- Locations
- 🇨🇦
St. Boniface General Hospital, Winnipeg, Manitoba, Canada
🇺🇸University of California - Los Angeles, Los Angeles, California, United States
🇨🇦Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2Hypertension
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT00240422
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Nürnberg, Germany
🇩🇪Friedrich-Alexander-Universität, Erlangen, Germany
🇩🇪Universität Erlangen-Nürnberg, Nürnberg, Germany
Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 311
- Registration Number
- NCT00239408
- Locations
- 🇵🇹
Hospital Garcia de Orta, Almada, Portugal
🇵🇹Unidade Funcional de Infecciologia, Barreiro, Portugal
🇵🇹Hospital Distrital de Faro, Faro, Portugal
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 196
- Registration Number
- NCT00239460
- Locations
- 🇺🇸
Attn: William C. Bailey, M.D., Birmingham, Alabama, United States
🇺🇸Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸The Oregon Clinic, Portland, Oregon, United States
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 429
- Registration Number
- NCT00239473
- Locations
- 🇨🇭
Ospedale San Giovanni, Bellinzona, Switzerland
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
🇮🇹Ospedale Silvestrini, San Sisto (pg), Italy
Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5
- Conditions
- Hypertension
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 713
- Registration Number
- NCT00239369
- Locations
- 🇫🇷
Hopital Avicenne, Bobigny, France
🇨🇳Boehringer Ingelheim Investigational Site, Taipei, Taiwan
🇫🇷Mg Recherches, Paris, France
Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 107
- Registration Number
- NCT00239499
- Locations
- 🇿🇦
Boehringer Ingelheim Investigational Site, Welkom, South Africa
🇿🇦Tijger Trial Centre, Bellville, South Africa
🇿🇦Durban Lung Centre, Durban, South Africa
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 131
- Registration Number
- NCT00239447
- Locations
- 🇺🇸
National Jewish Medical and Research Center, Denver, Colorado, United States
🇺🇸Division of Pulmonary and Critical Care Medicine, Little Rock, Arkansas, United States
🇺🇸LSU MC-Sheveport, Shreveport, Louisiana, United States
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 605
- Registration Number
- NCT00239421
- Locations
- 🇦🇹
Med. Uni.-Klinik Graz, Graz, Austria
🇩🇰Lungemedicinsk Forskning 2B, Aarhus, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen NV, Denmark